Advertisement
Screener

Acumen Pharmaceuticals, Inc. (ABOS) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value

Acumen Pharmaceuticals, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value

Acumen Pharmaceuticals, Inc. (ABOS) had Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value of $351.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-12.

Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue · last filed 2026-08-12

  • 2026-06-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value $351.00K.
  • 2026-03-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value $340.00K.
  • 2025-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value $346.00K.
  • 2025-09-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value $345.00K.
Period endShare-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value
2026-06-30$351.00K
10-Q · filed 2026-08-12
2026-03-31$340.00K
10-Q · filed 2026-05-12
2025-12-31$346.00K
10-K · filed 2026-03-26
2025-09-30$345.00K
10-Q · filed 2025-11-12
2025-06-30$344.00K
10-Q · filed 2025-08-12
2025-03-31$297.00K
10-Q · filed 2025-05-13
2024-12-31$2.02M
10-K · filed 2025-03-27
2024-09-30$4.19M
10-Q · filed 2024-11-12
2024-06-30$3.82M
10-Q · filed 2024-08-13
2024-03-31$8.06M
10-Q · filed 2024-05-14
2023-12-31$7.05M
10-K · filed 2024-03-26
2023-09-30$7.43M
10-Q · filed 2023-11-13
2023-06-30$8.82M
10-Q · filed 2023-08-08
2023-03-31$6.45M
10-Q · filed 2023-05-09
2022-12-31$8.71M
10-K · filed 2023-03-27
2022-09-30$17.77M
10-Q · filed 2022-11-14
2022-06-30$6.56M
10-Q · filed 2022-08-15
2022-03-31$4.80M
10-Q · filed 2022-05-16
2021-12-31$5.52M
10-K · filed 2022-03-28
2021-09-30$14.03M
10-Q · filed 2021-11-15

Similar stocks

Stock NameCountryMarket CapPE Ratio
Outlook Therapeutics, Inc. (OTLK)United States$0.162B-4.90
Humacyte, Inc. (HUMA)United States$0.155B-2.26
Voyager Therapeutics, Inc. (VYGR)United States$0.173B-1.99
PRECISION BIOSCIENCES INC (DTIL)United States$0.175B-3.95
Coherus Oncology, Inc. (CHRS)United States$0.182B-1.63
Tenaya Therapeutics, Inc. (TNYA)United States$0.140B-1.60
Alpha Cognition Inc. (ACOG)$0.185B-6.77
Caribou Biosciences, Inc. (CRBU)United States$0.134B-1.79
Armata Pharmaceuticals, Inc. (ARMP)United States$0.132B
Neumora Therapeutics, Inc. (NMRA)United States$0.132B-1.48